potent MAT2A inhibitor in vivo tool
efficacy in MTAP-mut. xenograft (50 mpk SC)
from fragment-based DD (frag. merging)
J. Med. Chem., Apr. 26, 2021
AstraZeneca, Cambridge, UK
compound 28
1 min read
The AstraZeneca MAT2a allosteric inhibitor, compound 28, is a remarkably potent (25 nM in cells) in vivo tool compound generated from merging of two weak fragments (Kd = 250 μM and 6.2 μM). The molecule binds in the same site as AG-270 (above) and has a relatively uncommon quinazolinone core, which makes several polar interactions in the binding site. The identification of this highly efficient inhibitor is a great case study for fragment-based lead generation.
Search By Structure
- RM-018
- GDC-0334
- BAY 1101042 (runcaciguat)
- AG-270
- NJH-2-057
- basmisanil
- STM-2457
- compound 28
- VT-104
- CB-5083
- compound 20p
- SHR168442
- GNE-9815
- ABD957
Molecules of the Month
2023
2022
2021
2020